We compared the physiologic and therapeutic consequences of deploying different MUC1 antigenic preparations such as non-glycosylated 9mers, O-glycosylated 9mers mimicking aberrant glycosylation, longer peptides containing class I and class II epitopes, and rotating lysates of naturally glycosylated MUC1-expressing tumor lines. Here, MUC1 is linked to neoplasm.